Literature DB >> 17575132

Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.

Vitalyi Senyuk1, Kislay K Sinha, Donglan Li, Ciro R Rinaldi, Sastry Yanamandra, Giuseppina Nucifora.   

Abstract

Recurring chromosomal translocations observed in human leukemia often result in the expression of fusion proteins that are DNA-binding transcription factors. These altered proteins acquire new dimerization properties that result in the assembly of inappropriate multimeric transcription complexes that deregulate hematopoietic programs and induce leukemogenesis. Recently, we reported that the fusion protein AML1/MDS1/EVI1 (AME), a product of a t(3;21)(q26;q22) associated with chronic myelogenous leukemia and acute myelogenous leukemia, displays a complex pattern of self-interaction. Here, we show that the 8th zinc finger motif of MDS1/EVI1 is an oligomerization domain involved not only in interaction of AME with itself but also in interactions with the parental proteins, RUNX1 and MDS1/EVI1, from which AME is generated. Because the 8th zinc finger motif is also present in the oncoprotein EVI1, we have evaluated the effects of the interaction between RUNX1 and EVI1 in vitro and in vivo. We found that in vitro, this interaction alters the ability of RUNX1 to bind to DNA and to regulate a reporter gene, whereas in vivo, the expression of the isolated 8th zinc finger motif of EVI1 is sufficient to block the granulocyte colony-stimulating factor-induced differentiation of 32Dcl3 cells, leading to cell death. As EVI1 is not detected in normal bone marrow cells, these data suggest that its inappropriate expression could contribute to hematopoietic transformation in part by a new mechanism that involves EVI1 association with key hematopoietic regulators, leading to their functional impairment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575132     DOI: 10.1158/0008-5472.CAN-06-3962

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.

Authors:  A E Marneth; K H M Prange; A S A Al Hinai; S M Bergevoet; N Tesi; E M Janssen-Megens; B Kim; N Sharifi; M L Yaspo; J Kuster; M A Sanders; E C G Stoetman; J Knijnenburg; T C J M Arentsen-Peters; C M Zwaan; H G Stunnenberg; M M van den Heuvel-Eibrink; T Haferlach; M Fornerod; J H Jansen; P J M Valk; B A van der Reijden; J H A Martens
Journal:  Leukemia       Date:  2017-09-05       Impact factor: 11.528

Review 2.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

3.  EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.

Authors:  Emilie A Bard-Chapeau; Jayantha Gunaratne; Pankaj Kumar; Belinda Q Chua; Julius Muller; Frederic A Bard; Walter Blackstock; Neal G Copeland; Nancy A Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

4.  Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.

Authors:  F Li; W He; R Geng; X Xie
Journal:  Clin Transl Oncol       Date:  2019-05-03       Impact factor: 3.405

5.  Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response.

Authors:  Sonja C Bingemann; Torsten A Konrad; Rotraud Wieser
Journal:  FEBS J       Date:  2009-10-16       Impact factor: 5.542

Review 6.  Common features of megakaryocytes and hematopoietic stem cells: what's the connection?

Authors:  Hui Huang; Alan B Cantor
Journal:  J Cell Biochem       Date:  2009-08-01       Impact factor: 4.429

7.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.

Authors:  Stefan Stein; Marion G Ott; Stephan Schultze-Strasser; Anna Jauch; Barbara Burwinkel; Andrea Kinner; Manfred Schmidt; Alwin Krämer; Joachim Schwäble; Hanno Glimm; Ulrike Koehl; Carolin Preiss; Claudia Ball; Hans Martin; Gudrun Göhring; Kerstin Schwarzwaelder; Wolf-Karsten Hofmann; Kadin Karakaya; Sandrine Tchatchou; Rongxi Yang; Petra Reinecke; Klaus Kühlcke; Brigitte Schlegelberger; Adrian J Thrasher; Dieter Hoelzer; Reinhard Seger; Christof von Kalle; Manuel Grez
Journal:  Nat Med       Date:  2010-01-24       Impact factor: 53.440

8.  Consistent up-regulation of Stat3 Independently of Jak2 mutations in a new murine model of essential thrombocythemia.

Authors:  Vitalyi Senyuk; Ciro Roberto Rinaldi; Donglan Li; Francesca Cattaneo; Aleksandra Stojanovic; Fabrizio Pane; Xiaoping Du; Nadim Mahmud; Jerome Dickstein; Giuseppina Nucifora
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

9.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.

Authors:  Hiromi Yamazaki; Mikiko Suzuki; Akihito Otsuki; Ritsuko Shimizu; Emery H Bresnick; James Douglas Engel; Masayuki Yamamoto
Journal:  Cancer Cell       Date:  2014-04-03       Impact factor: 31.743

10.  Mutations in MECOM, Encoding Oncoprotein EVI1, Cause Radioulnar Synostosis with Amegakaryocytic Thrombocytopenia.

Authors:  Tetsuya Niihori; Meri Ouchi-Uchiyama; Yoji Sasahara; Takashi Kaneko; Yoshiko Hashii; Masahiro Irie; Atsushi Sato; Yuka Saito-Nanjo; Ryo Funayama; Takeshi Nagashima; Shin-Ichi Inoue; Keiko Nakayama; Keiichi Ozono; Shigeo Kure; Yoichi Matsubara; Masue Imaizumi; Yoko Aoki
Journal:  Am J Hum Genet       Date:  2015-11-12       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.